Oral decitabine-cedazuridine in acute myeloid leukaemia.

IF 8.3 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

ACS Applied Materials & Interfaces Pub Date : 2024-11-01 Epub Date: 2024-09-23 DOI:10.1111/bjh.19769

Ian M Bouligny, Courtney D DiNardo

引用次数: 0

Abstract

In a randomized crossover study involving 89 patients with acute myeloid leukaemia ineligible for intensive chemotherapy, Geissler et al. compared intravenous decitabine and oral decitabine-cedazuridine. The pharmacokinetics and pharmacodynamics of the two formulations were similar. The clinical efficacy of oral decitabine-cedazuridine was consistent with historical data of intravenous decitabine. Commentary on: Geissler et al. Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. Br J Haematol 2024; 205:1734-1745.

查看原文本刊更多论文

口服地西他滨-西达脲苷治疗急性髓性白血病。

在一项涉及 89 名不符合强化化疗条件的急性髓性白血病患者的随机交叉研究中，Geissler 等人比较了静脉注射地西他滨和口服地西他滨-西达曲林。两种制剂的药代动力学和药效学相似。口服地西他滨-西达曲林的临床疗效与静脉注射地西他滨的历史数据一致。相关评论Geissler等人.急性髓性白血病口服地西他滨/卡佐尿苷与静脉注射地西他滨的比较：一项随机、交叉、注册、药代动力学研究。Doi: 10.1111/bjh.19741.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Materials & Interfaces 工程技术-材料科学：综合

CiteScore

16.00

自引率

6.30%

发文量

4978

审稿时长

1.8 months

期刊介绍： ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.